By Fineline Cube Transcenta Holdings Ltd (HKG: 6628) and its U.S. partner Inhibrx Biosciences, Inc. (NASDAQ: INBX) announced positive interim results from a Phase I/II study of ozekibart (INBRX-109) in combination with FOLFIRI for patients with locally advanced or metastatic, unresectable colorectal cancer (CRC). The precision-engineered tetravalent death receptor 5 (DR5) agonist antibody achieved a 20% objective response rate (ORR) in heavily pretreated patients, substantially exceeding historical benchmarks of 1-6%.
Clinical Trial Overview
| Item | Detail |
|---|---|
| Sponsors | Transcenta Holdings Ltd (HKG: 6628) & Inhibrx Biosciences, Inc. (NASDAQ: INBX) |
| Drug Candidate | Ozekibart (INBRX-109) |
| Mechanism | Tetravalent DR5 agonist antibody inducing tumor-selective cell death |
| Study Design | Phase I/II, ozekibart + FOLFIRI combination |
| Patient Population | Heavily pretreated locally advanced/metastatic unresectable CRC |
| Evaluable Patients | 45 |
| Concurrent Development | FDA market filing submitted last month for chondrosarcoma indication |
Key Efficacy Results
| Endpoint | Ozekibart + FOLFIRI | Historical Standard-of-Care |
|---|---|---|
| Objective Response Rate (ORR) | 20% | 1-6% |
| Median Progression-Free Survival (mPFS) | 5.5 months | ~3-4 months |
| Disease Control Rate (DCR) | 87% | ~50-60% |
Regulatory Status & Development Strategy
- Chondrosarcoma: Fast Track and Orphan Drug designations granted by U.S. FDA; market filing submitted April 2026
- Colorectal Cancer: Phase I/II interim data supports potential pivotal trial advancement
- Commercial Rights: Transcenta holds development and commercialization rights for mainland China, Hong Kong SAR, Macau SAR, and Taiwan region
- Mechanism Innovation: First-in-class tetravalent DR5 agonist designed to maximize tumor-selective apoptosis while minimizing systemic toxicity
Strategic Market Implications
The compelling efficacy data in a treatment-refractory CRC population addresses a significant unmet medical need, with current standard regimens showing minimal activity in heavily pretreated patients. The dual-indication strategy—pursuing both the rare chondrosarcoma indication and the broader CRC market—provides multiple pathways to commercial success.
Industry analysts note that DR5-targeted therapies have historically faced challenges with toxicity and limited efficacy, but ozekibart’s tetravalent engineering appears to overcome these limitations through enhanced tumor selectivity and potency.
Commercial Outlook & Competitive Positioning
- Market Opportunity: Addresses $8+ billion global metastatic CRC market with novel mechanism of action
- Regulatory Momentum: Chondrosarcoma filing could lead to first approval in 2027, followed by potential CRC indication
- Partnership Synergy: Combines Inhibrx’s U.S. development expertise with Transcenta’s Greater China commercial infrastructure
- Investment Attraction: Strong clinical data likely to enhance partnership and financing opportunities
- Therapeutic Differentiation: Novel DR5 mechanism offers alternative to existing targeted therapies and immunotherapies
Forward-Looking Statements
This brief contains forward-looking statements regarding clinical development, regulatory submissions, and commercial prospects. Actual results may differ due to regulatory decisions, clinical trial outcomes, and competitive dynamics in oncology therapeutics.-Fineline Info & Tech